2025
Does Stapling Platform Influence Robotic Sleeve Gastrectomy Postoperative Outcomes?
Ying L, Rutledge R, Butensky S, Lugo D, Morton J, Ringold F. Does Stapling Platform Influence Robotic Sleeve Gastrectomy Postoperative Outcomes? Obesity Surgery 2025, 35: 1838-1844. PMID: 40227538, PMCID: PMC12065732, DOI: 10.1007/s11695-025-07855-z.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseasePostoperative outcomesNo significant differenceSleeve gastrectomyRate of de novo GERDStapler useOverall side effect profileRetrospective single-surgeon studyLinear staplerPostoperative refluxOperative timePostoperative length of stayBackgroundLaparoscopic sleeve gastrectomyPostoperative gastroesophageal reflux diseaseRate of postoperative refluxSingle-surgeon studySide effect profileSignificant differenceWeight lossWeight loss surgeryRobotic-assisted sleeve gastrectomyLength of stayPostoperative lengthPatient demographicsEffect profileA narrative review on multimodal spinal anesthesia: Old technique and new use
Pierson D, Certoma R, Hobbs J, Cong X, Li J. A narrative review on multimodal spinal anesthesia: Old technique and new use. Journal Of Anesthesia And Translational Medicine 2025, 4: 25-32. PMID: 40321954, PMCID: PMC12048027, DOI: 10.1016/j.jatmed.2025.02.002.Peer-Reviewed Original ResearchMoving Beyond Desensitization to Tolerance in Food Allergy
Flom J, Shreffler W, Perrett K. Moving Beyond Desensitization to Tolerance in Food Allergy. The Journal Of Allergy And Clinical Immunology In Practice 2025, 13: 741-744. PMID: 40010566, DOI: 10.1016/j.jaip.2025.02.014.Peer-Reviewed Original ResearchManagement of IgE-mediated food allergyFood allergyIgE-mediated food allergyStages of clinical developmentSide effect profileMode of deliveryGoal of therapeuticsSustained unresponsivenessDosing regimensDose protocolProactive therapyAllergen-specificClinical developmentActive therapyPatient populationSide effectsTherapyPassive therapyPatient-specificDesensitizationClinical contextPatientsDoseAllergyDegree of protectionEffectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis
Sannaa W, Almasry M, Peedikayil M, Grimshaw A, Attamimi M, AlMutairdi A, Al-Bawardy B. Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis. Therapeutic Advances In Gastroenterology 2025, 18: 17562848241312766. PMID: 39802627, PMCID: PMC11719443, DOI: 10.1177/17562848241312766.Peer-Reviewed Original ResearchOral vancomycin therapyPrimary sclerosing cholangitisIBD-PSCInflammatory bowel diseasePooled analysisClinical responseSclerosing cholangitisEpisodes of acute cholangitisFavorable side effect profilePooled analysis of studiesSystematic reviewInflammatory bowel disease associated with primary sclerosing cholangitisSide effect profileLong-term safetyClinical response/remissionVancomycin therapyOral vancomycinClinical remissionEndoscopic remissionAcute cholangitisMedian durationImmunosuppressive agentsNo episodesConcomitant treatmentEffect profile
2024
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do A, Zahrawi F, Mehal W. Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH). Nature Reviews Drug Discovery 2024, 24: 171-189. PMID: 39609545, DOI: 10.1038/s41573-024-01084-2.Peer-Reviewed Original ResearchSide effect profileTrial end pointsCombination of therapeuticsReverse many aspectsFatty acid synthase inhibitorGenetic susceptibility factorsPlacebo responseEffect profileFibrosis reversalTreated patientsClinical studiesLiver inflammationSynthase inhibitorLiver diseaseTherapeutic approachesClinical useEnd pointsSteatotic liver diseaseTherapeutic landscapeMetabolic environmentHepatocyte deathSusceptibility factorsChronic overnutritionGlobal epidemicLiverToxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
Hunter C, Bewersdorf J, Mendez L, Podoltsev N, Zeidan A, Eighmy W, Roeder H, Malinis M, Shallis R. Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia. Blood 2024, 144: 1480-1480. DOI: 10.1182/blood-2024-211250.Peer-Reviewed Original ResearchInvasive fungal infectionsAcute myeloid leukemiaAntifungal prophylaxisDiagnosed AMLDrug-drug interactionsTransaminase elevationVisual disturbancesRates of invasive fungal infectionsInvasive fungal infections incidenceBaseline ANCCD4 countMyeloid leukemiaAllogeneic stem cell transplantationAnti-fungal prophylaxisAcute myeloid leukemia diagnosisDuration of neutropeniaBaseline CD4 countLess-intensive therapyStem cell transplantationPatient baseline characteristicsSide effect profileCandida sppTriazole agentsWilcoxon rank sum testAntifungal voriconazoleChallenges in management of older patients with chronic myeloid leukemia
Stempel J, Shallis R, Wong R, Podoltsev N. Challenges in management of older patients with chronic myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1219-1232. PMID: 38652861, DOI: 10.1080/10428194.2024.2342559.Peer-Reviewed Original ResearchChronic myeloid leukemiaTyrosine kinase inhibitorsTreatment-free remissionOlder patientsMyeloid leukemiaTyrosine kinase inhibitor dosingGeneration tyrosine kinase inhibitorsManagement of older patientsSecond-line agentsSurvival of patientsSide effect profileFront-line optionPrevalence of comorbiditiesImproved survivalCardiovascular toleranceEffect profileFavorable outcomeKinase inhibitorsPrevent progressionPatientsPersonalized treatmentQuality of lifeTreatment goalsOptimal careDiscontinuation strategies
2023
Advantages and Disadvantages of Nutraceuticals
Rajalakshmi R, Melians M, Pon F, Cosio D, Buvarahamurthy V, Jayakumar A, Paidas M. Advantages and Disadvantages of Nutraceuticals. Nutritional Neurosciences 2023, 245-286. DOI: 10.1007/978-981-99-0677-2_15.Peer-Reviewed Original ResearchEfficacy of nutraceuticalsHeavy metalsLimitations of nutraceuticalsPoor bioavailabilityDrug bioavailabilityBioavailabilityNutraceutical marketLack of experimental evidencePrevent chronic diseasesContaminationPatient health issuesSide effectsHealth professionalsNutrientsNutraceuticalsSide effect profileMetalChronic diseasesRaw materialsHealth issuesToxicityToxic side effectsCompoundsDrug-drug interactionsBlood-brain barrierPlasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions
Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.Peer-Reviewed Original ResearchConceptsNeuro-immunological diseaseIntravenous immunoglobulinAutoimmune neurological disordersAutoimmune neuromuscular disorderAdult patientsElderly patientsNeurological disordersNeuromuscular disordersChronic inflammatory demyelinating polyradiculoneuropathyNational Inpatient Sample databaseNational Inpatient Sample datasetInflammatory demyelinating polyradiculoneuropathySafe therapeutic choiceRetrospective chart reviewAppropriate clinical settingSide effect profileDemyelinating polyradiculoneuropathyIVIG useChart reviewYounger patientsMyasthenia gravisEffect profileMedical historyPrimary diagnosisTherapeutic choiceImpact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel J, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko J, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon K, Goetz M, Haddad T, Iwata H, Jassem J, Lee S, Linderholm B, Los M, Mamounas E, Miller K, Morris P, Munzone E, Gal-Yam E, Ring A, Shepherd L, Singer C, Thomssen C, Tseng L, Valagussa P, Winer E, Wolff A, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck A, DeMichele A, Gnant M, Cameron D, El-Abed S, Rugo H, Steger G, Traina T, Werutsky G, Wolmark N. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. Journal Of Clinical Oncology 2023, 41: 5118-5130. PMID: 37556775, DOI: 10.1200/jco.23.00126.Peer-Reviewed Original ResearchConceptsImpact of BMIPALLAS trialBMI categoriesHigher BMIEarly hormone receptor-positive breast cancerHormone receptor-positive breast cancerReceptor-positive breast cancerAddition of palbociclibEfficacy of palbociclibEarly treatment discontinuationRelative dose intensityTreatment discontinuation ratesDisease-free survivalSide effect profileMultivariable logistic regressionBreast cancer riskSignificant decreaseNeutropenia ratesPalbociclib armEndocrine therapyTreatment discontinuationDiscontinuation ratesDose intensityEarly discontinuationNormal weightReduced Pain and Improved Function Following Short-Term Use of Noninvasive BioWave High Frequency Peripheral Nerve Stimulation for Pain Management
Abd-Elsayed A, Gyorfi M, Fischman M, Odonkor C, Siff B, Cyr K. Reduced Pain and Improved Function Following Short-Term Use of Noninvasive BioWave High Frequency Peripheral Nerve Stimulation for Pain Management. Pain And Therapy 2023, 12: 553-562. PMID: 36807084, PMCID: PMC10036714, DOI: 10.1007/s40122-023-00480-7.Peer-Reviewed Original ResearchPain scoresMedication useHigh-frequency peripheral nerve stimulationNoninvasive neuromodulationSafe side effect profileOverall pain reductionOverall pain scorePain treatment modalitiesDaily living scoreSide effect profileChronic pain patientsRetrospective pilot studyChronic pain reliefNeuromodulation systemPeripheral nervous systemCost-effective therapyPeripheral nerve stimulationShort-term useOverall painPain reductionPain reliefPlacebo groupWeeks patientsLiving scoreTherapy duration
2022
Polycystic Kidney Disease Drug Development: A Conference Report
Liebau M, Mekahli D, Perrone R, Soyfer B, Fedeles S. Polycystic Kidney Disease Drug Development: A Conference Report. Kidney Medicine 2022, 5: 100596. PMID: 36698747, PMCID: PMC9867973, DOI: 10.1016/j.xkme.2022.100596.Peer-Reviewed Original ResearchAutosomal dominant polycystic kidney diseasePolycystic kidney diseaseAutosomal recessive polycystic kidney diseaseRecessive polycystic kidney diseaseKidney diseaseProgression of ADPKDSide effect profileChronic kidney failureDisease-modifying therapiesAutosomal dominant polycystic liver diseasePolycystic liver diseaseTotal kidney volumeDominant polycystic kidney diseaseCritical Path InstituteMechanism of actionCommon monogenic disorderDrug development toolsEffect profileLiver diseaseKidney failureOutcomes ConsortiumEnrichment biomarkerClinical trialsKidney volumeSurrogate endpointsEmraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
Krystal J, Kane J, Correll C, Walling D, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. The Lancet 2022, 400: 2210-2220. PMID: 36528376, DOI: 10.1016/s0140-6736(22)01990-0.Peer-Reviewed Original ResearchConceptsTreatment of schizophreniaPositive allosteric modulatorsAdverse eventsUS sitesAllosteric modulatorsFavorable side effect profileMini International Neuropsychiatric InterviewNovel positive allosteric modulatorReceptor positive allosteric modulatorExtrapyramidal symptom assessmentMultiple ascending dosesCommon adverse eventsPhase 1b trialPlacebo-controlled studySide effect profileInternational Neuropsychiatric InterviewCohort of participantsAscending dosesSafety populationPrimary endpointBlood pressureM4 receptorsTreatment initiationDaily treatmentOral dosesOverall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients
Marvin JE, Azar MM, Belfield KD, Do V, Formica R, Cohen EA. Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients. Progress In Transplantation 2022, 32: 351-356. PMID: 36039533, DOI: 10.1177/15269248221122894.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsProportion of patientsBelatacept conversionInfectious complicationsTransplant recipientsExact testLong-term infectious complicationsFavorable side effect profileOverall infectious complicationsSide effect profileTime of transplantFisher's exact testT-testStudent's t-testMann-Whitney UInduction immunosuppressionTacrolimus patientsKidney transplantMore patientsPrimary outcomeEffect profileTacrolimusOutcome dataHigh incidenceRetrospective evaluationIncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effectsEnhanced Recovery After Surgery: Opioid Sparing Strategies After Discharge: A Review
Rajput K, Shergill S, Chow RM, Vadivelu N, Kaye AD. Enhanced Recovery After Surgery: Opioid Sparing Strategies After Discharge: A Review. Current Pain And Headache Reports 2022, 26: 93-102. PMID: 35072920, DOI: 10.1007/s11916-022-01009-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOpioid usePersistent post-surgical painNon-opioid strategiesNon-opioid therapiesOpioid-sparing strategiesOverprescribing of opioidsPostoperative pain scoresMultimodal analgesic approachPost-surgical painSide effect profileNon-opioid analgesicsRecent FindingsSeveral studiesERAS protocolOpioid protocolAnalgesic approachBreakthrough painHospital stayMultimodal analgesiaPain scoresAcute painOral ketaminePostoperative periodEffect profilePatient recoveryGood quality researchMedical Therapy with Antimuscarinics and ß3-Agonists
Goodridge S, Rickey L. Medical Therapy with Antimuscarinics and ß3-Agonists. 2022, 147-164. DOI: 10.1007/978-3-030-84352-6_8.Peer-Reviewed Original ResearchOveractive bladderManagement of OABTreatment of OABMedical therapy optionsSecond-line therapyFirst-line treatmentSide effect profileBeta-3 agonistQuality of lifeMedical therapyEffect profileTherapy optionsDrug classesComparative efficacyBehavioral modificationAntimuscarinicsBladderTherapyEfficacyTreatmentPharmacotherapyPatientsAgonistsLarge subsetProgression
2021
Early Interventions for Clinical High-Risk State for Psychosis
ERZİN G, GÜLÖKSÜZ S. Early Interventions for Clinical High-Risk State for Psychosis. Nöro Psikiyatri Arşivi 2021, 58: s7-s11. PMID: 34658629, PMCID: PMC8498818, DOI: 10.29399/npa.27404.Peer-Reviewed Original ResearchClinical high-risk stateHigh-risk stateHigh riskPopulation-based approachCommunity-based youth mental health servicePotential side effect profileYouth mental health servicesSide effect profileTreatment of choiceHigh-risk groupMental health centersPrevention approachesMental health servicesClinical high riskEarly intervention optionsHigh-risk conceptOutcome of psychosisIntervention optionsCognitive behavioral therapyPsychosis incidenceAggressive interventionHealth centersGeneral populationSide effectsEarly interventionAn Overview of Anxiety, Trauma-Related and Obsessive-Compulsive Disorders
Conroy M, van Dyck L, Lane C, Cook J. An Overview of Anxiety, Trauma-Related and Obsessive-Compulsive Disorders. Current Geriatrics Reports 2021, 10: 91-100. DOI: 10.1007/s13670-021-00361-x.Peer-Reviewed Original ResearchObsessive-compulsive disorderOlder adultsOverview of anxietyPurpose of ReviewAnxietyPsychosocial interventionsMental health conditionsPsychosocial consequencesMental health specialistsAnxietyOlder patientsPsychiatric disordersInappropriate medication useFirst-line treatmentSide effect profilePrimary care settingSymptomatologyDisordersAdultsAmerican Geriatrics SocietyHealth specialistsBeers criteriaMedication useEffect profilePharmacological treatmentPatient symptomatologyEtonogestrel contraceptive implant uptake and safety among solid organ transplant recipients
Lew J, Sheeder J, Lazorwitz A. Etonogestrel contraceptive implant uptake and safety among solid organ transplant recipients. Contraception 2021, 104: 556-560. PMID: 34147509, PMCID: PMC8502202, DOI: 10.1016/j.contraception.2021.06.007.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsOrgan transplant recipientsReproductive-age womenEtonogestrel contraceptive implantContraceptive implant usersTransplant recipientsContraceptive implantsCommon transplant-related complicationPost-transplant infectionsSafe contraceptive optionTransplant-related outcomesRetrospective cohort studyTransplant-related complicationsGraft-related complicationsSide effect profileTertiary medical centerRisk of pregnancyImplant usersContraceptive implant useAdditional health risksPregnancy patternsCohort studyGraft complicationsGraft rejectionEffect profile
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply